Working... Menu

Survival Prolongation by Rationale Innovative Genomics (SPRING)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03386929
Recruitment Status : Recruiting
First Posted : December 29, 2017
Last Update Posted : August 1, 2018
ARC Foundation for Cancer Research
Information provided by (Responsible Party):
Worldwide Innovative Networking Association

Brief Summary:
Patients with advanced/metastatic non-small cell lung cancer (NSCLC) with no documented targetable alterations (Epidermal Growth Factor Receptor (EGFR) mutation, Anaplastic Lymphoma Kinase (ALK) translocation, ROS1 mutation if available or MET exon 14 skipping mutation if available) will receive a tri-therapy associating avelumab, axitinib and palbociclib.

Condition or disease Intervention/treatment Phase
Non-small Cell Lung Cancer Metastatic Non-Small Cell Lung Cancer Stage IIIB Drug: Avelumab Drug: Axitinib Drug: Palbociclib Phase 1 Phase 2

Detailed Description:
During the Phase 1 (approximately 30 patients), the tri-therapy will be tested at different doses following a specific dose-escalation scheme (3 + 3 model) in order to establish the safety and identify the Maximum Tolerated Dose (MTD) and recommended dose (RP2D) for the Phase 2. The phase 2 will confirm the safety and will assess the clinical utility of the tri-therapy approach in the treatment of advanced/metastatic NSCLC (100 patients). The study will also explore the clinical utility of the Simplified Interventional Mapping System (SIMS), a new tool/algorithm enabling matching of NSCLC patients with combination therapy. For this purpose tumor/metastasis and matched normal tissue biopsies will be requested in order to obtain sequencing and expression profiles.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 130 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Proof of Concept Study to Explore Safety and Efficacy of Tri-therapy Approach in Advanced/Metastatic NSCLC and Retrospectively Assess the Ability of Integrated Genomics and Transcriptomics to Match Patients to the Combination
Actual Study Start Date : November 29, 2017
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : December 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Avelumab, Axitinib, Palbociclib

For the Phase 1:

Avelumab is administered intravenously (IV) on Day 1 and Day 15 of each Cycle (one cycle = 28 days) in combination with axitinib po bid and palbociclib po (7 days off; 21 days on).

For the Phase 2:

Avelumab, axitinib and palbociclib are administered at the recommended dose (RP2D) as determined during the phase 1 part of the study.

Drug: Avelumab
A human antibody of the immunoglobulin gamma-1 isotype that specifically targets and blocks the Programmed Death ligand (PD-L1) for PD-1.
Other Name: Bavencio

Drug: Axitinib
A selective oral (tablet) inhibitor of tyrosine kinases Vascular Endothelial Growth Factor (VEGF) receptors 1, 2, and 3. These receptors are implicated in pathologic angiogenesis, tumor growth and cancer progression.
Other Name: Inlyta

Drug: Palbociclib
A selective, reversible oral (capsule) inhibitor of cyclin-dependent kinases (CDK) 4 and 6. The inhibition of CDK 4/6 blocks DNA synthesis by prohibiting progression of the cell cycle from G1 to S phase.
Other Name: Ibrance

Primary Outcome Measures :
  1. Dose Limiting Toxicity (DLT) [ Time Frame: Cycle 1 Days 1-28 (28 days from date of first dose of study treatment) ]
    DLT is assessed by NCI CTCAE v4.03

  2. Incidence of the tested 3-Drug Combination Therapy-Emergent Adverse Events and Serious Adverse Events [ Time Frame: From informed consent signature through 90 days after administration of the treatment (last dose) ]
    The occurrence of adverse events and serious adverse events reported from the signing of an informed consent through 90 days after the last administration of the treatment will be summarized for all subjects who received at least one dose of the study treatment (safety population) and will be evaluated based on NCI CTCAE v4.03: June 14, 2010.

  3. Response Rate (RR) [ Time Frame: Baseline up to approximately 24 months ]
    Response rate is defined as the proportion of participants with reduction in tumor burden of a predefined amount based on RECIST 1.1 evaluation

  4. Duration of the Response [ Time Frame: Baseline up to approximately 24 months ]
    Duration of Response (DR) is defined for patients with confirmed objective response (Complete Response [CR] or Partial Response [PR]) as the time from the first documentation of objective tumor response to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first.

  5. Progression-Free Survival (PFS) [ Time Frame: Baseline up to approximately 24 months ]
    Progression Free Survival (PFS) is defined as the time from the first dose of study treatment to the date of disease progression by RECIST 1.1 or death due to any cause, whichever occurs first.

  6. Overall Survival (OS) [ Time Frame: Baseline up to approximately 24 months ]
    OS is defined as the time from the first dose of study treatment to the date of death due to any cause.

  7. SIMS Algorithm to Predict Clinical Outcome [ Time Frame: 4 years ]
    The proportion of participants whose SIMS analysis matches the treatment combination, will be correlated retrospectively to clinical outcome.

Secondary Outcome Measures :
  1. Incidence of Treatment-related and or Biopsy-related Serious Adverse Events [ Time Frame: 4 years ]
    The occurrence of treatment-related and or biopsy-related serious adverse events as assessed by NCI CTCAE v4.03 will be summarized for all study subjects.

  2. Genomic and Transcriptomic Profile [ Time Frame: 4 years ]
    Genomic (DNA) and transcriptomic (RNA) aberrations (mutations, translocations, rearrangements and changes in expression level) identified in the study population (Non-Small Cell Lung) will be described.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  1. Age: Men and women aged ≥ 18 years,
  2. Signed written informed consent,
  3. Any histologic type of locally advanced or metastatic NSCLC,
  4. Life expectancy of ≥ 12 weeks,
  5. Measurable or evaluable (cytologically or radiologically detectable disease such as ascites, peritoneal deposits, or lesions which do not fulfill RECIST 1.1 criteria for measurable disease) lesions according to RECIST v1.1 criteria for phase 1 portion. For phase 2, all patients must have RECIST 1.1 measurable disease,
  6. Physiologic function:

    • Hematologic function: Absolute neutrophil count (ANC) ≥ 1.5 × 109/L, platelet count ≥ 100 × 109/L, and hemoglobin ≥ 9 g/dL (may have been transfused),
    • Hepatic function: Total bilirubin level ≤ 1.5 × the upper limit of normal (ULN) range and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels ≤ 2.5 × ULN,
    • Renal function: Estimated creatinine clearance ≥ 30 mL/min according to the Cockcroft-Gault formula (or local institutional standard method).
  7. Pregnancy and contraception:

    • Pregnancy test: Negative serum or urine pregnancy test at screening for women of childbearing potential,
    • Contraception: Highly effective contraception for both male and female subjects throughout the study and for 90 days after last avelumab treatment administration if the risk of conception exists.
  8. Ability to comply with protocol requirements,
  9. Willingness to consent and ability to undergo a trucut biopsy to obtain a fresh metastasis or primary tumor biopsy in case no adequate tumoral tissue is available, and to undergo fibroscopy to obtain a biopsy from normal bronchial mucosa,
  10. No serious or medically uncontrolled concomitant conditions that are likely to make the patient unfit for SPRING combination therapy, as per investigator assessment,
  11. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.


  1. Patients with documented oncogenic aberrations at enrollment: EGFR, ALK, ROS1 when available, MET exon 14 skipping when available.

    Note: For Phase 1 portion, all patients with adenocarcinoma histology must have documentation of results for druggable oncogenic aberrations (EGFR mutations, ALK rearrangements, and ROS1 when available) prior to enrollment on the study.

  2. For Phase 1 portion, >2 lines of prior therapy in the metastatic setting.
  3. For the dose escalation phase of the study or until the MTD for the combination regimen has been determined, patients with moderate hepatic impairment defined as AST, ALT, alkaline phosphatase (ALP) >5 times ULN, which would be grade 3 or higher. However patients with liver metastases with AST/ALT ≤ 5 x ULN can be included in the study.
  4. For Phase 2 portion, any prior therapy in the metastatic setting.

Clinical exclusion criteria for Phase 1 and Phase 2 studies:

  1. Documented untreated central nervous system metastases (indicated by clinical symptoms, cerebral edema, steroid requirement, or progressive disease in the prior four weeks),
  2. Participants with a history of myocardial infarction within the last 2 years or with significant cardiac arrhythmias uncontrolled by medication or pacemaker,
  3. Participants with any history of interstitial lung disease,
  4. Prior clinically significant toxicities from anticancer agents or radiotherapy which have not regressed to Grade ≤ 1 severity (NCI-CTCAE version 4.03) apart from peripheral neuropathy and alopecia,
  5. History of any second malignancy in the last two years; patients with prior history of in-situ cancer or basal or squamous cell skin cancer are eligible. Patients with a history of other malignancies are eligible if they have been continuously disease-free for at least two years,
  6. Autoimmune condition requiring medical intervention,
  7. Uncontrolled concomitant illness, active infection requiring i.v. antibiotics,
  8. Participants who are at risk for, or who have a history of arterial thromboembolic events within the past 12 months and/or venous thromboembolic events within the past 6 months, or have had any recent active gastrointestinal bleeding,
  9. Prior > G3 hemoptysis, major blood vessel involvement, and/or central cavitations,
  10. Known or suspected drug hypersensitivity to any drug used in the combination,
  11. Difficulty swallowing, malabsorption or other chronic gastrointestinal disease, or conditions that may hamper compliance and/or absorption of the oral drugs,
  12. Any condition (e.g., known or suspected poor compliance, psychological instability, geographical location, etc.) that, in the judgment of the investigator may affect the patient's ability to sign the informed consent and undergo study procedures,
  13. Taking another experimental drugs within 28 days prior to day 1 of the protocol medications in this study,
  14. Pregnant or breast-feeding women,
  15. Both male and female patients of reproductive potential must agree to use a reliable method of birth control, during the study and for 3 months following the last dose of study drug,
  16. Patients currently taking strong CYP3A4 inducers and inhibitors.
  17. Patients currently taking proton pump inhibitors due to their impact on the disposition of palbociclib during the dose escalation phase,
  18. Other anticancer agents and anticoagulants are excluded (except for low doses of anticoagulants used for access lines)
  19. A time period of at least three weeks or five drug half-lives, whichever is shorter must have elapsed from last non-investigational therapy before day 1 of treatment on this study,
  20. Specific exclusion criteria for administration of avelumab, in combination:

    • IMMUNOSUPRESSANTS: Current use of immunosuppressive medication, EXCEPT for the following: a. intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection); b. Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent; c. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).
    • AUTOIMMUNE DISEASE: Active autoimmune disease that might deteriorate when receiving an immuno-stimulatory agent. Patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment are eligible.
    • ORGAN TRANSPLANTATION: Prior organ transplantation including allogenic stem-cell transplantation.
    • INFECTIONS: Active infection requiring systemic therapy.
    • HIV/AIDS: Known history of testing positive for HIV or known acquired immunodeficiency syndrome.
    • HEPATITIS: Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive HBV surface antigen or HCV RNA if anti-HCV antibody screening test positive).
    • VACCINATION: Vaccination within 4 weeks of the first dose of avelumab and while on trials is prohibited except for administration of inactivated vaccines.
    • HYPERSENSITIVITY TO STUDY DRUG: Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v4.03 Grade ≥ 3).
    • CARDIOVASCULAR DISEASE: Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (≥ New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication.
    • OTHER PERSISTING TOXICITIES: Persisting toxicity related to prior therapy (NCI CTCAE v. 4.03 Grade > 1); however, alopecia, sensory neuropathy Grade ≤ 2, or other Grade ≤ 2 not constituting a safety risk based on investigator's judgment are acceptable.
    • Other severe acute or chronic medical conditions including colitis, inflammatory bowel disease, pneumonitis, pulmonary fibrosis or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03386929

Layout table for location contacts
Contact: FANNY WUNDER, PhD 0033145595843

Layout table for location information
United States, California
UCSD Moores Cancer Center Recruiting
La Jolla, California, United States, 92093
Contact: Sarah MOORE   
Principal Investigator: Lyudmila BAZHENOVA, MD         
United States, South Dakota
Avera Cancer Center Recruiting
Sioux Falls, South Dakota, United States, 57105
Contact: Martha LANG   
Principal Investigator: Benjamin SOLOMON, MD         
Centre Léon Bérard Recruiting
Lyon, France, 69008
Contact: Séverine LAURENT   
Principal Investigator: Pierre SAINTIGNY, MD         
Chiam Sheba Medical Center Recruiting
Ramat Gan, Israel, 5265601
Contact: Yona GILADY   
Principal Investigator: Jair BAR, MD         
Centre Hospitalier Luxembourg Recruiting
Luxembourg, Luxembourg, 1210
Contact: Lucile PERNOT   
Principal Investigator: Guy BERCHEM, MD         
Vall Hebron Institute of Oncology Recruiting
Barcelona, Spain, 08035
Contact: LLuisa CARBONELL   
Principal Investigator: Enriqueta Felip, MD         
Sponsors and Collaborators
Worldwide Innovative Networking Association
ARC Foundation for Cancer Research
Layout table for investigator information
Principal Investigator: RAZELLE KURZROCK, MD University of California, San Diego

Additional Information:
Layout table for additonal information
Responsible Party: Worldwide Innovative Networking Association Identifier: NCT03386929     History of Changes
Other Study ID Numbers: WIN001
2017-001455-32 ( EudraCT Number )
First Posted: December 29, 2017    Key Record Dates
Last Update Posted: August 1, 2018
Last Verified: July 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Worldwide Innovative Networking Association:
dual matched normal and tumor biopsies
SIMS algorithm
Gene expression

Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Antibodies, Monoclonal
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunologic Factors
Physiological Effects of Drugs